Cancer Blood Test Articles & Analysis
22 news found
The peer-reviewed article published in the journal Frontiers in Oncology (article), shows that the prostate cancer test based on CTC harvested with the ISET® technology and identified by the Immuno-Cytochemistry (ICC) PSA marker has an estimated positive-predictive-value (PPV) of 99% and negative-predictive-value (NPV) of 97%, providing a more reliable ...
Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. ...
Commenting on the lawsuit, John Saia, the company’s SVP, General Counsel and Corporate Secretary, said: “At Guardant Health, our mission for the last 10 years has been to develop groundbreaking blood tests that improve cancer care and save patients’ lives. ...
“We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and ...
“This broad partnership will tap into our portfolio of end to end solutions to generate meaningful evidence and help optimize Lilly’s therapy development, and ultimately bring more targeted treatment options to cancer patients.” “We are pleased to collaborate with a widely-utilized and experienced laboratory like Foundation Medicine to ensure broad access ...
Importantly, the President’s plan recognizes that the rigorous study of multi-cancer detection blood tests, to date, has brought us to a crucial inflection point where detecting many cancers at once is now an essential pillar of any effort to end cancer as we know it ...
“Unfortunately, many people do not follow recommended screening guidelines for lung cancer. We believe a simple blood test could help improve screening rates and detect lung cancer early, when it can most easily be ...
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri®, GRAIL’s multi-cancer early detection (MCED) blood test. OHSU will provide patients access to ...
’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test. Under the partnership, Premier’s PINC AI will augment its ...
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection ...
Through tissue or blood samples, FoundationOne CDx and FoundationOne Liquid CDx evaluate more than 300 genes known to drive cancer growth and identify patients who may be eligible for specific targeted therapies, immunotherapies or clinical trials. In-network coverage of FoundationOne CDx and FoundationOne Liquid CDx testing will support broader ...
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced that the New York State Department of Health (NYSDOH) has approved Galleri™, GRAIL’s groundbreaking multi-cancer early detection blood test. ...
As part of an initial pilot focused on oncology, the company is calling for proposals dedicated to gene fusions in solid tumors and molecular testing in blood cancers. Grant proposals are now being accepted through Oct. 31, 2020. ...
Combining forces with Illumina enables broader and faster adoption of GRAIL’s innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach. ...
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, ...
Pennsylvania June 8th, 2020: The FDA has granted Breakthrough Device Designation for Seravue® to support earlier diagnosis of Liver Cancer using a simple blood test. Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, ...
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced that its chief medical officer, Mark Stovsky, MD, participated in an Impact Session at the 2019 Medical Innovation Summit organized by Cleveland Clinic. ...
Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases, including hepatocellular carcinoma or HCC, the most common form of ...
Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver ...
Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases. Glycotest employs unique non-invasive blood ...